286 related articles for article (PubMed ID: 9427258)
1. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
[TBL] [Abstract][Full Text] [Related]
2. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel.
Kwon JS; Elit L; Finn M; Hirte H; Mazurka J; Moens F; Trim K
Gynecol Oncol; 2002 Mar; 84(3):420-5. PubMed ID: 11855881
[TBL] [Abstract][Full Text] [Related]
3. Single-dose dexamethasone paclitaxel premedication.
Micha JP; Rettenmaier MA; Dillman R; Fraser P; Birk C; Brown JV
Gynecol Oncol; 1998 May; 69(2):122-4. PubMed ID: 9600818
[TBL] [Abstract][Full Text] [Related]
4. A simplified premedication schedule for 1-hour paclitaxel administration.
Tsavaris N; Kosmas C; Vadiaka M
J Support Oncol; 2005; 3(1):77-81. PubMed ID: 15724950
[TBL] [Abstract][Full Text] [Related]
5. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
Sasada S; Hirashima T; Nakamura Y; Takimoto T; Furukawa M; Kobayashi M; Nitta T; Matsui K; Kawase I
Int J Clin Oncol; 2007 Aug; 12(4):274-8. PubMed ID: 17701006
[TBL] [Abstract][Full Text] [Related]
6. [Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma].
Kobierski J; Majdak E; Mielcarek P; Emerich J
Ginekol Pol; 2002 Nov; 73(11):1015-20. PubMed ID: 12722392
[TBL] [Abstract][Full Text] [Related]
7. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK
Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
[TBL] [Abstract][Full Text] [Related]
8. A simplified premedication protocol for one-hour paclitaxel infusion in various combinations.
Kosmas C; Tsavaris N
Med Sci Monit; 2006 Nov; 12(11):CR462-6. PubMed ID: 17072270
[TBL] [Abstract][Full Text] [Related]
9. One-hour paclitaxel infusion schedules: a phase I/II comparative trial.
Greco FA; Hainsworth JD
Semin Oncol; 1995 Jun; 22(3 Suppl 6):118-23. PubMed ID: 7597427
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel plus carboplatin in the treatment of ovarian cancer.
Ozols RF
Semin Oncol; 1999 Feb; 26(1 Suppl 2):84-9. PubMed ID: 10190787
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy of advanced ovarian cancer: current status and future directions.
Ozols RF; Vermorken JB
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-1-S2-9. PubMed ID: 9045324
[TBL] [Abstract][Full Text] [Related]
12. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Ann Oncol; 1997 Jun; 8(6):611-4. PubMed ID: 9261533
[TBL] [Abstract][Full Text] [Related]
13. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis for paclitaxel hypersensitivity reactions.
Kintzel PE
Ann Pharmacother; 2001 Sep; 35(9):1114-7. PubMed ID: 11573863
[TBL] [Abstract][Full Text] [Related]
15. [Administration of premedication with fexofenadine for paclitaxel-induced hypersensitive reactions in breast cancer patients complicated with closed-angle glaucoma].
Komatsubara K; Miyoshi K; Kogure Y; Matsuhisa T; Eguchi H
Gan To Kagaku Ryoho; 2010 Jan; 37(1):107-10. PubMed ID: 20087041
[TBL] [Abstract][Full Text] [Related]
16. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy.
Sendo T; Sakai N; Itoh Y; Ikesue H; Kobayashi H; Hirakawa T; Nakano H; Oishi R
Cancer Chemother Pharmacol; 2005 Jul; 56(1):91-6. PubMed ID: 15791461
[TBL] [Abstract][Full Text] [Related]
17. The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients.
de Castro Baccarin AL; Irene MN; de Iracema Gomes Cubero D; Luz AS; Castro SN; Sordi R; Móz LES; Del Giglio A
Support Care Cancer; 2019 Mar; 27(3):927-931. PubMed ID: 30069696
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of short-time premedication with d-chlorpheniramine maleate injection for paclitaxel-induced hypersensitivity reaction].
Harada T; Doi M; Yamada Y; Akase T
Gan To Kagaku Ryoho; 2008 Aug; 35(8):1347-51. PubMed ID: 18701846
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
Ozols RF
Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119
[TBL] [Abstract][Full Text] [Related]
20. Incorporation of paclitaxel and carboplatin in combined-modality therapy for locally advanced non-small cell lung cancer.
Belani CP
Semin Oncol; 1999 Feb; 26(1 Suppl 2):44-54. PubMed ID: 10190783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
